目的 探討伊馬替尼輔助重組人干擾素α-2b治療慢性髓性白血?。–ML）患者的效果。方法 將2012年9月-2016年8月選擇在漢中三二〇一醫(yī)院血液科治療的CML患者90例，隨機(jī)分為各45例患者的實(shí)驗(yàn)組與對(duì)照組，對(duì)照組給予重組人干擾素α-2b治療，實(shí)驗(yàn)組在對(duì)照組治療的基礎(chǔ)上給予伊馬替尼輔助治療，兩組都治療觀察3個(gè)月。比較兩組的遺傳學(xué)療效、血液學(xué)療效，檢測(cè)血清血管內(nèi)皮生長(zhǎng)因子（VEGF）和堿性成纖維細(xì)胞生長(zhǎng)因子（bFGF）變化情況，并隨訪觀察兩組的生存狀況。結(jié)果 治療后實(shí)驗(yàn)組的完全細(xì)胞遺傳學(xué)緩解（CCyR）率為88.9%，對(duì)照組為75.6%，實(shí)驗(yàn)組顯著高于對(duì)照組（P<0.05）。治療后實(shí)驗(yàn)組與對(duì)照組的總有效率分別為73.3%和51.1%，實(shí)驗(yàn)組顯著高于對(duì)照組（P<0.05）。實(shí)驗(yàn)組與對(duì)照組治療后的血清VEGF和bFGF含量與治療前對(duì)比顯著降低（P<0.05），治療后實(shí)驗(yàn)組也比對(duì)照組顯著降低（P<0.05）。隨訪至今，實(shí)驗(yàn)組的生存期和無(wú)病生存期都顯著長(zhǎng)于對(duì)照組（P<0.05）。結(jié)論 伊馬替尼輔助重組人干擾素α-2b治療CML能抑制血清VEGF和bFGF的表達(dá)，改善血液學(xué)和遺傳學(xué)療效，故而達(dá)到延長(zhǎng)患者生存時(shí)間的目的。

Objective To investigate the effects of recombinant human interferon α-2b combined with imatinib in the treatment of patients with chronic myeloid leukemia(CML). Methods From September 2012 to August 2016, 90 patients with CML in our hospital department of hematology for treatment were selected as the research object, all the patients were divided into experimental group and control group with 45 patients in each group accorded randomly, the control group was treated with recombinant human interferon α-2b, the experimental group was treated with recombinant human interferon α-2b combined with imatinib, two groups were treated for 3 months. Results After treatment, the incidence of CCyR in the experimental group was 88.9%, so that was 75.6% in the control group, and the observation group was higher than that of the control group (P<0.05). After treatment, the total effective rates in the experimental group and the control group were 73.3% and 51.1%, respectively, and the experimental group was higher than that of the control group (P<0.05). The serum levels of VEGF and bFGF in the experimental group and the control group after treatment were significantly lower than those before treatment (P<0.05). After treatment, the experimental group were also significantly lower than that of the control group (P<0.05). After followed-up, the survival and disease-free survival times in the experimental group were significantly higher than those of the control group (P<0.05). Conclusion The recombinant human interferon α-2b combined with imatinib in the treatment of patients with chronic myeloid leukemia can inhibit the expression of serum VEGF and bFGF, improve the hematological and genetic efficacy, and prolong the survival time.